Další formáty:
BibTeX
LaTeX
RIS
@article{1774677,
author = {Pavelek, Zbysek and Sobisek, Lukas and Sarlakova, Jana and Potuznik, Pavel and Peterka, Marek and Stetkarova, Ivana and Štourač, Pavel and Mares, Jan and Hradilek, Pavel and Ampapa, Radek and Grunermelova, Marketa and Vachova, Marta and Recmanova, Eva and Angelucci, Francesco and Haluskova, Simona and Valis, Martin},
article_location = {LAUSANNE},
article_number = {JAN 2021},
doi = {http://dx.doi.org/10.3389/fneur.2020.593527},
keywords = {multiple sclerosis; treatment; long-term therapy; clinical practice; DMD},
language = {eng},
issn = {1664-2295},
journal = {FRONTIERS IN NEUROLOGY},
title = {Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS},
url = {https://www.frontiersin.org/articles/10.3389/fneur.2020.593527/full},
volume = {11},
year = {2021}
}
TY - JOUR
ID - 1774677
AU - Pavelek, Zbysek - Sobisek, Lukas - Sarlakova, Jana - Potuznik, Pavel - Peterka, Marek - Stetkarova, Ivana - Štourač, Pavel - Mares, Jan - Hradilek, Pavel - Ampapa, Radek - Grunermelova, Marketa - Vachova, Marta - Recmanova, Eva - Angelucci, Francesco - Haluskova, Simona - Valis, Martin
PY - 2021
TI - Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS
JF - FRONTIERS IN NEUROLOGY
VL - 11
IS - JAN 2021
SP - 1-12
EP - 1-12
PB - FRONTIERS MEDIA SA
SN - 16642295
KW - multiple sclerosis
KW - treatment
KW - long-term therapy
KW - clinical practice
KW - DMD
UR - https://www.frontiersin.org/articles/10.3389/fneur.2020.593527/full
N2 - Background: Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system. Well-established drugs used for MS patients after the first demyelinating event in the Czech Republic include glatiramer acetate (GA), interferon beta-1a (IFN beta-1a), IFN beta-1b (IFN beta-1b), peginterferon beta-1a (peg-IFN beta-1a), and teriflunomide. Objective: The objective of this observational study was to compare the effectiveness of the abovementioned drugs in patients with MS who initiated their therapy after the first demyelinating event. Patients were followed for up to 2 years in real clinical practice in the Czech Republic. Methods: A total of 1,654 MS patients treated after the first demyelinating event and followed up for 2 years were enrolled. Evaluation parameters (endpoints) included the annualized relapse rate (ARR), time to next relapse, change in the Expanded Disability Status Scale (EDSS) score, and time of confirmed disease progression (CDP). When patients ended the therapy before the observational period, the reason for ending the therapy among different treatments was compared. Results: No significant difference was found among the groups of patients treated with IFN beta-1a/1b, GA, or teriflunomide for the following parameters: time to the first relapse, change in the EDSS score, and the proportion of patients with CDP. Compared to IFN beta-1a (44 mcg), a significant increase in the percentage of relapse-free patients was found for GA, but this treatment effect was not confirmed by the validation analysis. Compared to the other drugs, there was a significant difference in the reasons for terminating GA therapy. Conclusion: Small differences were found among GA, IFN beta and teriflunomide therapies, with no significant impact on the final outcome after 2 years. Therefore, in clinical practice, we recommend choosing the drug based on individual potential risk from long-term therapy and on patient preferences and clinical characteristics.
ER -
PAVELEK, Zbysek, Lukas SOBISEK, Jana SARLAKOVA, Pavel POTUZNIK, Marek PETERKA, Ivana STETKAROVA, Pavel ŠTOURAČ, Jan MARES, Pavel HRADILEK, Radek AMPAPA, Marketa GRUNERMELOVA, Marta VACHOVA, Eva RECMANOVA, Francesco ANGELUCCI, Simona HALUSKOVA a Martin VALIS. Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS. \textit{FRONTIERS IN NEUROLOGY}. LAUSANNE: FRONTIERS MEDIA SA, 2021, roč.~11, JAN 2021, s.~1-12. ISSN~1664-2295. Dostupné z: https://dx.doi.org/10.3389/fneur.2020.593527.
|
